Details of the Drug

General Information of Drug (ID: DM6LOQU)

Drug Name

Celecoxib

Synonyms

CEL; Celebra; Celebrex; Celecox; Celecoxi; Celocoxib; Eurocox; Medicoxib; Onsenal; Solexa; Xilebao; Celecoxib [Old RN]; Celecoxib [USAN]; Pfizer brand of celecoxib; SC 58635; SC58635; YM 177; YM177; AI-525; CEP-33222; Celebra (TN); Celebrex (TN); SC-58635; TPI-336; YM-177; Celebrex, Celebra, Celecoxib; Celecoxib (SC-58635); Celecoxib (JAN/USAN/INN); SC-58553, SC-58635; P-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide; Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl); 4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Approved	[1], [2]
Pain	MG30-MG3Z	Phase 3	[1], [2]

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

381.4

Topological Polar Surface Area (xlogp)

3.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination: 2% of drug is excreted from urine in the unchanged form [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 17.48915 micromolar/kg/day [4]
Water Solubility: The ability of drug to dissolve in water is measured as 0.005 mg/mL [3]

Chemical Identifiers

Formula: C17H14F3N3O2S
IUPAC Name: 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
Canonical SMILES: CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
InChI: InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
InChIKey: RZEKVGVHFLEQIL-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2662
ChEBI ID: CHEBI:41423
CAS Number: 169590-42-5
DrugBank ID: DB00482
TTD ID: D03RTS
VARIDT ID: DR00520
INTEDE ID: DR0286
ACDINA ID: D00113

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[5], [6], [7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[9]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[10]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[11]
Sulfotransferase 1A1 (SULT1A1)	DEYWLRK	ST1A1_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Rheumatoid arthritis

ICD Disease Classification

FA20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 2 (COX-2)	DTT	PTGS2	7.93E-04	-0.29	-0.34
Sulfotransferase 1A1 (SULT1A1)	DME	SULT1A1	8.47E-01	3.57E-02	1.73E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	1.82E-04	-1.35E-01	-5.84E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Celecoxib

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sulfasalazine	DMICA9H	Moderate	Increased risk of nephrotoxicity by the combination of Celecoxib and Sulfasalazine.	Rheumatoid arthritis [FA20]	[64]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Dexamethasone.	Rheumatoid arthritis [FA20]	[65]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Celecoxib and Leflunomide.	Rheumatoid arthritis [FA20]	[66]
-----------

Coadministration of a Drug Treating the Disease Different from Celecoxib (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Celecoxib and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[67]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Celecoxib and Repaglinide.	Acute diabete complication [5A2Y]	[68]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Celecoxib and Glibenclamide.	Acute diabete complication [5A2Y]	[68]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Celecoxib and Tolazamide.	Acute diabete complication [5A2Y]	[68]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Celecoxib and Nateglinide.	Acute diabete complication [5A2Y]	[68]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Celecoxib and Glipizide.	Acute diabete complication [5A2Y]	[68]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Celecoxib caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[69]
Oliceridine	DM6MDCF	Moderate	Decreased metabolism of Celecoxib caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[70]
Galantamine	DMEO794	Moderate	Decreased metabolism of Celecoxib caused by Galantamine mediated inhibition of CYP450 enzyme.	Alzheimer disease [8A20]	[71]
Donepezil	DMIYG7Z	Minor	Decreased metabolism of Celecoxib caused by Donepezil mediated inhibition of CYP450 enzyme.	Alzheimer disease [8A20]	[72]
Metronidazole	DMTIVEN	Moderate	Decreased metabolism of Celecoxib caused by Metronidazole mediated inhibition of CYP450 enzyme.	Amoebiasis [1A36]	[70]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Celecoxib and Inotersen.	Amyloidosis [5D00]	[69]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Celecoxib and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[73]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Celecoxib caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[67]
Zafirlukast	DMHNQOG	Moderate	Decreased metabolism of Celecoxib caused by Zafirlukast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[70]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Budesonide.	Asthma [CA23]	[65]
Desipramine	DMT2FDC	Moderate	Decreased metabolism of Celecoxib caused by Desipramine mediated inhibition of CYP450 enzyme.	Attention deficit hyperactivity disorder [6A05]	[70]
Ofloxacin	DM0VQN3	Moderate	Additive CNS depression effects by the combination of Celecoxib and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[74]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Celecoxib and Kanamycin.	Bacterial infection [1A00-1C4Z]	[75]
Ciprofloxacin XR	DM2NLS9	Moderate	Additive CNS depression effects by the combination of Celecoxib and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[74]
Trovafloxacin	DM6AN32	Moderate	Additive CNS depression effects by the combination of Celecoxib and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[74]
Sulfamethoxazole	DMB08GE	Moderate	Decreased metabolism of Celecoxib caused by Sulfamethoxazole mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[70]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS depression effects by the combination of Celecoxib and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[74]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Celecoxib and Streptomycin.	Bacterial infection [1A00-1C4Z]	[75]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Celecoxib and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[74]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS depression effects by the combination of Celecoxib and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[74]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Celecoxib and ABT-492.	Bacterial infection [1A00-1C4Z]	[74]
Gentamicin	DMKINJO	Moderate	Increased risk of nephrotoxicity by the combination of Celecoxib and Gentamicin.	Bacterial infection [1A00-1C4Z]	[75]
Netilmicin	DMRD1QK	Moderate	Increased risk of nephrotoxicity by the combination of Celecoxib and Netilmicin.	Bacterial infection [1A00-1C4Z]	[75]
Levofloxacin	DMS60RB	Moderate	Additive CNS depression effects by the combination of Celecoxib and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[74]
Tobramycin	DMUI0CH	Moderate	Increased risk of nephrotoxicity by the combination of Celecoxib and Tobramycin.	Bacterial infection [1A00-1C4Z]	[75]
Lomefloxacin	DMVRH9C	Moderate	Additive CNS depression effects by the combination of Celecoxib and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[74]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Etidronic acid.	Bone paget disease [FB85]	[76]
Risedronate	DM5FLTY	Moderate	Increased risk of nephrotoxicity by the combination of Celecoxib and Risedronate.	Bone paget disease [FB85]	[76]
Alendronate	DMY2KX9	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Alendronate.	Bone paget disease [FB85]	[76]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Celecoxib and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[77]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Celecoxib caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[78]
Tamoxifen	DMLB0EZ	Major	Decreased metabolism of Celecoxib caused by Tamoxifen mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[79]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Celecoxib and Iodipamide.	Cholelithiasis [DC11]	[80]
Dihydrocodeine	DMB0FWL	Moderate	Decreased metabolism of Celecoxib caused by Dihydrocodeine mediated inhibition of CYP450 enzyme.	Chronic pain [MG30]	[70]
Anisindione	DM2C48U	Moderate	Increased plasma concentrations of Celecoxib and Anisindione due to competitive inhibition of the same metabolic pathway.	Coagulation defect [3B10]	[81]
Oxaliplatin	DMQNWRD	Moderate	Decreased renal excretion of Celecoxib caused by Oxaliplatin mediated nephrotoxicity.	Colorectal cancer [2B91]	[82]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Celecoxib and Drospirenone.	Contraceptive management [QA21]	[83]
Methoxyflurane	DML0RAE	Moderate	Increased risk of nephrotoxicity by the combination of Celecoxib and Methoxyflurane.	Corneal disease [9A76-9A78]	[69]
Dextromethorphan	DMUDJZM	Moderate	Decreased metabolism of Celecoxib caused by Dextromethorphan mediated inhibition of CYP450 enzyme.	Cough [MD12]	[67]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Celecoxib caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[84]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Celecoxib caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[85]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Celecoxib caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[86]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Celecoxib caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[87]
Aprepitant	DM053KT	Moderate	Increased metabolism of Celecoxib caused by Aprepitant mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[88]
Sertraline	DM0FB1J	Moderate	Decreased metabolism of Celecoxib caused by Sertraline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[70]
Trimipramine	DM1SC8M	Moderate	Decreased metabolism of Celecoxib caused by Trimipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[70]
Nortriptyline	DM4KDYJ	Moderate	Decreased metabolism of Celecoxib caused by Nortriptyline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[70]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Celecoxib caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[70]
OPC-34712	DMHG57U	Major	Decreased metabolism of Celecoxib caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[89]
Clomipramine	DMINRKW	Moderate	Decreased metabolism of Celecoxib caused by Clomipramine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[70]
Trazodone	DMK1GBJ	Moderate	Decreased metabolism of Celecoxib caused by Trazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[70]
Amoxapine	DMKITQE	Moderate	Decreased metabolism of Celecoxib caused by Amoxapine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[70]
Doxepin	DMPI98T	Moderate	Decreased metabolism of Celecoxib caused by Doxepin mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[70]
Maprotiline	DMPWB7T	Moderate	Decreased metabolism of Celecoxib caused by Maprotiline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[70]
Fenfluramine	DM0762O	Moderate	Decreased metabolism of Celecoxib caused by Fenfluramine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[70]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Celecoxib and Cannabidiol.	Epileptic encephalopathy [8A62]	[69]
Ethacrynic acid	DM60QMR	Moderate	Antagonize the effect of Celecoxib when combined with Ethacrynic acid.	Essential hypertension [BA00]	[90]
Benzthiazide	DMQWZ0H	Moderate	Antagonize the effect of Celecoxib when combined with Benzthiazide.	Essential hypertension [BA00]	[90]
Tolterodine	DMSHPW8	Minor	Decreased metabolism of Celecoxib caused by Tolterodine mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[91]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Celecoxib caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[92]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Celecoxib caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[70]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Celecoxib caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[70]
Eplerenone	DMF0NQR	Moderate	Increased risk of hyperkalemia by the combination of Celecoxib and Eplerenone.	Heart failure [BD10-BD1Z]	[93]
Carvedilol	DMHTEAO	Moderate	Decreased metabolism of Celecoxib caused by Carvedilol mediated inhibition of CYP450 enzyme.	Heart failure [BD10-BD1Z]	[70]
Chlorothiazide	DMLHESP	Moderate	Antagonize the effect of Celecoxib when combined with Chlorothiazide.	Heart failure [BD10-BD1Z]	[90]
Furosemide	DMMQ8ZG	Moderate	Antagonize the effect of Celecoxib when combined with Furosemide.	Heart failure [BD10-BD1Z]	[90]
Amiloride	DMRTSGP	Moderate	Antagonize the effect of Celecoxib when combined with Amiloride.	Heart failure [BD10-BD1Z]	[90]
Bumetanide	DMRV7H0	Moderate	Antagonize the effect of Celecoxib when combined with Bumetanide.	Heart failure [BD10-BD1Z]	[90]
Hydroflumethiazide	DMVPUQI	Moderate	Antagonize the effect of Celecoxib when combined with Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[90]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Celecoxib caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[70]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Celecoxib caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[94]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Celecoxib caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[95]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Celecoxib and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[96]
Delavirdine	DM3NF5G	Minor	Decreased metabolism of Celecoxib caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[70]
Efavirenz	DMC0GSJ	Moderate	Decreased metabolism of Celecoxib caused by Efavirenz mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[70]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Celecoxib caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[97]
Gemfibrozil	DMD8Q3J	Moderate	Decreased metabolism of Celecoxib caused by Gemfibrozil mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[70]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Celecoxib caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[67]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Celecoxib and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[98]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Celecoxib and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[66]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Celecoxib and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[99]
Penbutolol	DM4ES8F	Moderate	Decreased metabolism of Celecoxib caused by Penbutolol mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[70]
Nebivolol	DM7F1PA	Moderate	Decreased metabolism of Celecoxib caused by Nebivolol mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[70]
Indapamide	DMGN1PW	Moderate	Antagonize the effect of Celecoxib when combined with Indapamide.	Hypertension [BA00-BA04]	[90]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Celecoxib when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[90]
Labetalol	DMK8U72	Moderate	Decreased metabolism of Celecoxib caused by Labetalol mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[70]
Hydrochlorothiazide	DMUSZHD	Moderate	Antagonize the effect of Celecoxib when combined with Hydrochlorothiazide.	Hypertension [BA00-BA04]	[90]
Fludrocortisone	DMUDIR8	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[65]
Balsalazide	DMO091F	Moderate	Increased risk of nephrotoxicity by the combination of Celecoxib and Balsalazide.	Indeterminate colitis [DD72]	[64]
Propiomazine	DMKY8V1	Moderate	Decreased metabolism of Celecoxib caused by Propiomazine mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[70]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Celecoxib and Methotrexate.	Leukaemia [2A60-2B33]	[69]
Ibandronate	DM0QZBN	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Ibandronate.	Low bone mass disorder [FB83]	[69]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Celecoxib and Porfimer Sodium.	Lung cancer [2C25]	[100]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Celecoxib caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[67]
Chloroquine	DMSI5CB	Moderate	Decreased metabolism of Celecoxib caused by Chloroquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[70]
Primaquine	DMWQ16I	Moderate	Decreased metabolism of Celecoxib caused by Primaquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[70]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Celecoxib and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[101]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Celecoxib and Idelalisib.	Mature B-cell leukaemia [2A82]	[102]
Clofarabine	DMCVJ86	Moderate	Increased risk of nephrotoxicity by the combination of Celecoxib and Clofarabine.	Mature B-cell lymphoma [2A85]	[69]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Celecoxib caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[69]
Propranolol	DM79NTF	Moderate	Decreased metabolism of Celecoxib caused by Propranolol mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[70]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Celecoxib and Exjade.	Mineral absorption/transport disorder [5C64]	[103]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Deflazacort.	Muscular dystrophy [8C70]	[65]
Methoxsalen	DME8FZ9	Moderate	Increased risk of photosensitivity reactions by the combination of Celecoxib and Methoxsalen.	Mycosis fungoides [2B01]	[67]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Celecoxib caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[104]
Promethazine	DM6I5GR	Moderate	Decreased metabolism of Celecoxib caused by Promethazine mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[70]
Ondansetron	DMOTQ1I	Moderate	Decreased metabolism of Celecoxib caused by Ondansetron mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[70]
Dexfenfluramine	DMJ7YDS	Moderate	Decreased metabolism of Celecoxib caused by Dexfenfluramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[70]
Metolazone	DMB39LO	Moderate	Antagonize the effect of Celecoxib when combined with Metolazone.	Oedema [MG29]	[90]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Celecoxib when combined with Polythiazide.	Oedema [MG29]	[90]
Diclofenac	DMPIHLS	Moderate	Increased risk of hepatotoxicity by the combination of Celecoxib and Diclofenac.	Osteoarthritis [FA00-FA05]	[105]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Celecoxib caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[106]
Pentazocine	DM1XBHS	Moderate	Decreased metabolism of Celecoxib caused by Pentazocine mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[70]
Dextropropoxyphene	DM23HCX	Moderate	Decreased metabolism of Celecoxib caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[70]
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Aspirin.	Pain [MG30-MG3Z]	[107]
Methamphetamine	DMPM4SK	Moderate	Decreased metabolism of Celecoxib caused by Methamphetamine mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[70]
Hydrocodone	DMQ2JO5	Moderate	Decreased metabolism of Celecoxib caused by Hydrocodone mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[70]
Oxycodone	DMXLKHV	Moderate	Decreased metabolism of Celecoxib caused by Oxycodone mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[70]
Prednisone	DM2HG4X	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Prednisone.	Postoperative inflammation [1A00-CA43]	[65]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[65]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Celecoxib caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[108]
Tamsulosin	DM5QF9V	Moderate	Decreased metabolism of Celecoxib caused by Tamsulosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[109]
Levomepromazine	DMIKFEL	Moderate	Decreased metabolism of Celecoxib caused by Levomepromazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[70]
Fluphenazine	DMIT8LX	Moderate	Decreased metabolism of Celecoxib caused by Fluphenazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[70]
Triflupromazine	DMKFQJP	Moderate	Decreased metabolism of Celecoxib caused by Triflupromazine mediated inhibition of CYP450 enzyme.	Psychotic disorder [6A20-6A25]	[70]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Celecoxib caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[110]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Celecoxib and Everolimus.	Renal cell carcinoma [2C90]	[111]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Celecoxib and Temsirolimus.	Renal cell carcinoma [2C90]	[111]
Gatifloxacin	DMSL679	Moderate	Additive CNS depression effects by the combination of Celecoxib and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[74]
Oxamniquine	DM2QDX1	Moderate	Decreased metabolism of Celecoxib caused by Oxamniquine mediated inhibition of CYP450 enzyme.	Schistosomiasis [1F86]	[70]
Mesoridazine	DM2ZGAN	Moderate	Decreased metabolism of Celecoxib caused by Mesoridazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[70]
Thioridazine	DM35M8J	Major	Decreased metabolism of Celecoxib caused by Thioridazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[112]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Celecoxib caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[113]
Haloperidol	DM96SE0	Moderate	Decreased metabolism of Celecoxib caused by Haloperidol mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[70]
Perphenazine	DMA4MRX	Moderate	Decreased metabolism of Celecoxib caused by Perphenazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[70]
Trifluoperazine	DMKBYWI	Moderate	Decreased metabolism of Celecoxib caused by Trifluoperazine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[70]
Risperidone	DMN6DXL	Moderate	Decreased metabolism of Celecoxib caused by Risperidone mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[70]
Pimozide	DMW83TP	Major	Decreased metabolism of Celecoxib caused by Pimozide mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[114]
Methylprednisolone	DM4BDON	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[65]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Celecoxib and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[69]
Prednisolone	DMQ8FR2	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[65]
Pitolisant	DM8RFNJ	Moderate	Decreased metabolism of Celecoxib caused by Pitolisant mediated inhibition of CYP450 enzyme.	Somnolence [MG42]	[69]
Disulfiram	DMCL2OK	Moderate	Decreased metabolism of Celecoxib caused by Disulfiram mediated inhibition of CYP450 enzyme.	Substance abuse [6C40]	[70]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Celecoxib and Naltrexone.	Substance abuse [6C40]	[115]
Warfarin	DMJYCVW	Moderate	Increased plasma concentrations of Celecoxib and Warfarin due to competitive inhibition of the same metabolic pathway.	Supraventricular tachyarrhythmia [BC81]	[81]
Sirolimus	DMGW1ID	Major	Increased risk of nephrotoxicity by the combination of Celecoxib and Sirolimus.	Transplant rejection [NE84]	[111]
Tacrolimus	DMZ7XNQ	Major	Increased risk of nephrotoxicity by the combination of Celecoxib and Tacrolimus.	Transplant rejection [NE84]	[111]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Celecoxib and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[68]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Celecoxib and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[68]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Celecoxib and Olsalazine.	Ulcerative colitis [DD71]	[64]
Cinoxacin	DM4EWNS	Moderate	Additive CNS depression effects by the combination of Celecoxib and Cinoxacin.	Urinary tract infection [GC08]	[74]
Sulfamethizole	DMGCHDS	Moderate	Decreased metabolism of Celecoxib caused by Sulfamethizole mediated inhibition of CYP450 enzyme.	Urinary tract infection [GC08]	[70]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Celecoxib and Plazomicin.	Urinary tract infection [GC08]	[75]
Nalidixic acid	DMRM0JV	Moderate	Additive CNS depression effects by the combination of Celecoxib and Nalidixic acid.	Urinary tract infection [GC08]	[74]
Triamcinolone	DM98IXF	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Celecoxib and Triamcinolone.	Vasomotor/allergic rhinitis [CA08]	[65]
Methdilazine	DMAUHQX	Moderate	Decreased metabolism of Celecoxib caused by Methdilazine mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[70]
Trimeprazine	DMEMV9D	Moderate	Decreased metabolism of Celecoxib caused by Trimeprazine mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[70]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Celecoxib caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[70]
Flecainide	DMSQDLE	Moderate	Decreased metabolism of Celecoxib caused by Flecainide mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[70]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Celecoxib caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[70]
-----------


⏷ Show the Full List of 166 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
FD&C red no. 3	E00629	Not Available	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 29 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Celecoxib 50 mg capsule	50 mg	Oral Capsule	Oral
Celecoxib 400 mg capsule	400 mg	Oral Capsule	Oral
Celecoxib 100 mg capsule	100 mg	Oral Capsule	Oral
Celecoxib 200 mg capsule	200 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2892).
2	New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
3	BDDCS applied to over 900 drugs
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Pfizer. Product Development Pipeline. March 31 2009.
6	Synflorix, GlaxoSmithKline's pneumococcal vaccine, receives European authorisation. GlaxoSmithKline. March 31 2009.
7	Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
8	Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000 May;293(2):453-9.
9	Celecoxib is a substrate of CYP2D6: impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227.
10	Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
11	Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510.
12	Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus. Aquat Toxicol. 2007 Mar 10;81(3):286-92.
13	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22	Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
23	Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
24	Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
25	Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
26	Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
27	Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
28	Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94.
29	Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
30	Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23.
31	Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
32	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
33	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
34	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
35	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
36	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
37	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
38	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
39	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
40	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
41	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
42	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
43	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
44	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
45	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
46	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
47	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
48	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
49	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
50	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
51	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
52	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
53	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
54	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
55	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
56	Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
57	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
58	Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
59	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
60	Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
61	Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
62	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
63	Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
64	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
65	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
66	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
67	Cerner Multum, Inc. "Australian Product Information.".
68	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
69	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
70	Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
71	Product Information. Reminyl (galantamine) Janssen Pharmaceuticals, Titusville, NJ.
72	Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
73	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
74	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
75	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
76	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
77	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
78	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
79	Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
80	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
81	Haase KK, Roias-Fernandez CH "Potential interaction between celecoxib and warfarin." Ann Pharmacother 34 (2000): 666-7. [PMID: 10852097]
82	Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
83	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
84	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
85	Cerner Multum, Inc. "Canadian Product Information.".
86	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
87	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
88	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
89	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
90	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
91	Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
92	Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
93	Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
94	Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao Y "Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers." Drug Metabol Drug Interact 19 (2003): 287-95. [PMID: 14768975]
95	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
96	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
97	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
98	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
99	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
100	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
101	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
102	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
103	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
104	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
105	Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
106	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
107	Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
108	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
109	Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
110	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
111	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
112	Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
113	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
114	Canadian Pharmacists Association.
115	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.